Long-term metastatic melanoma survival dramatically improves on immunotherapy: Study ETHealthWorldHalf of advanced melanoma patients live for 10 years with double drug treatment The GuardianBristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms Yahoo FinanceUChicago, one of the first to try new cancer therapy, treats woman’s life-threatening melanoma Crain’s Chicago BusinessNeoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma AJMC.com Managed Markets Network Long-term metastatic melanoma survival dramatically improves on immunotherapy: Study ETHealthWorldHalf of advanced melanoma patients live for 10 years with double drug treatment The GuardianBristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms Yahoo FinanceUChicago, one of the first to try new cancer therapy, treats woman’s life-threatening melanoma Crain’s Chicago BusinessNeoadjuvant Immunotherapy Superior to Targeted Therapy in Stage III Melanoma AJMC.com Managed Markets Network Top stories – Google News